Abstract | Severe congenital neutropenias are a heterogeneous group of rare haematological diseases characterized by impaired maturation of neutrophil granulocytes. Patients with severe congenital neutropenia are prone to recurrent, often life-threatening infections beginning in their first months of life. The most frequent pathogenic defects are autosomal dominant mutations in ELANE, which encodes neutrophil elastase, and autosomal recessive mutations in HAX1, whose product contributes to the activation of the granulocyte colony-stimulating factor (G-CSF) signalling pathway. The pathophysiological mechanisms of these conditions are the object of extensive research and are not fully understood. Furthermore, severe congenital neutropenias may predispose to myelodysplastic syndromes or acute myeloid leukaemia. Molecular events in the malignant progression include acquired mutations in CSF3R (encoding G-CSF receptor) and subsequently in other leukaemia-associated genes (such as RUNX1) in a majority of patients. Diagnosis is based on clinical manifestations, blood neutrophil count, bone marrow examination and genetic and immunological analyses. Daily subcutaneous G-CSF administration is the treatment of choice and leads to a substantial increase in blood neutrophil count, reduction of infections and drastic improvement of quality of life. Haematopoietic stem cell transplantation is the alternative treatment. Regular clinical assessments (including yearly bone marrow examinations) to monitor treatment course and detect chromosomal abnormalities (for example, monosomy 7 and trisomy 21) as well as somatic pre-leukaemic mutations are recommended. measurement of the blood ANC early in life. The physi cian's awareness and availability of basic diagnostic tools are also contributing factors. Most infants worldwide do not have a complete blood cell count done at birth, and most cases of neutropenia early in life are attributable to prematurity or immunological mechanisms. For this reason, severe congenital neutropenia is usually an inferred diagnosis based on fever and recurrent infec tions early in life and a measurement of the blood ANC associated with these events.
Inheritance
Demographics also play an important part in epidemio logy. Worldwide, autosomal dominant disorders seem to be more common, whereas the recessive disorders are usually diagnosed in consanguineous populations. Differences in the rate of consanguinity are prob ably the main reason that could explain the observed differences in the prevalence of specific neutropenia associated mutations between Europe and North America. For example, the prevalence of severe congenital neutro penia due to mutations in HAX1 (which encodes HCLS1associated protein X1 (HAX1)) in Europe is high (11% of cases of severe congenital neutropenia), probably owing to the large number of consanguine ous families of Turkic or Arabic origin. By contrast, in the United States, no patients with HAX1 mutations have been detected so far. In Israel, a unique pattern of mutations with a high prevalence of G6PC3 (which encodes glucose6phosphatase) mutations (25%) was found 5 . These data are very useful in clinical practice. When using genetic sequencing to confirm a diagnosis of severe congenital neutropenia, sequencing ELANE (which encodes neutrophil elastase) should be consid ered first, as mutations in ELANE are most common, unless the family history of the patient and clinical clues from the physical examination or general laboratory testing suggest otherwise. As targeted next generation sequencing and exome sequencing become more widely used as diagnostic tools, we can expect that new variants associated with severe congenital neutro penia will be identified, adding to our knowledge and perhaps making diagnosis somewhat more confusing.
Other hereditary factors are involved in determining the prevalence of congenital neutropenia. Individuals of African heritage have lower ANCs than individuals of white European or Asian origin 6 . Within the African heritage group, the presence of a specific polymorphism in DARC (encoding the Duffy antigen) has been linked with neutropenia 6, 7 . This condition is now often referred to as 'benign ethnic neutropenia' , as it is not associated with infections or evolution to myeloid malignancies. There are other forms of benign ethnic neutropenia and probably others to be discovered 7 . Interestingly, individuals carrying the neutropeniaassociated Duffy antigen are not predisposed to develop other forms of neutro penia, as reflected by the scarcity of people of African heritage in the Severe Chronic Neutropenia International Registry (SCNIR) or in the French Neutropenia Registry. Right: in a bone marrow smear stained with haematoxylin and eosin of a patient with severe congenital neutropenia, there are no mature granulocytes and increased numbers of promyelocytes (black arrow). The morphology of promyelocytes is also different: in patients with severe congenital neutropenia, promyelocytes have multiple vacuoles, a bulked nucleus and are much bigger than promyelocytes of healthy individuals. CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor; MPP, multipotent progenitor; ST-HSC, short-term haematopoietic stem cell.
Mortality
The mortality rate for severe congenital neutropenia before the antibiotic era (1950s) was as high as 90% 8 , and even with antibiotics, >80% of patients would die from severe bacterial infections 9 . A breakthrough in the treatment of severe congenital neutropenias occurred with the availability of recombinant granulocyte colony stimulating factor (GCSF) for clinical use 10 
(FIG. 2).
Treatment with GCSF resulted in an increase in the neutrophil count to >1 × 10 9 cells per l , and a significant decrease in the number and severity of infectious episodes, leading to a dramatic improvement of the quality of life 14 . The clinical benefits of GCSF therapy were clearly demonstrated in a phase III clin ical trial 14 . Intriguingly, granulocyte-macrophage colony stimulating factor (GMCSF) did not lead to an increase in the ANC in the majority of patients 13 .
In 2017, GCSF is the treatment of choice for severe congenital neutropenias. Overall survival is now estim ated to exceed 80%, including patients developing malignancies 15, 16 , although approximately 10% of patients (mainly GCSF nonresponders) still die from sepsis or severe bacterial infections 3, 16, 17 . In patients without nonhaematological involvement, survival mainly depends on their response to GCSF treatment, whereas in the subtypes of severe congenital neutro penias that also present with extra haematopoietic manifestations, survival depends on both the sever ity of neutropenia and the organ defects. For exam ple, in Barth syndrome, which is a severe congenital neutropenia associated with congestive heart failure (TABLE 1), survival is approximately 51% at 5 years and largely depends on the severity of heart failure and the availability of a heart transplantation 18 . However, because genetic analyses of severe congenital neutro penias are relatively recent and the majority of patients are children, adolescents and young adults, there are limited data correlating age, risk factors and life expec tancy for each specific aetiology of severe congenital neutro penia. Evolution to myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) are other major possible complications; data from the SCNIR indicate that the cumulative incidence of leukaemia was estimated to be 22% after 10 years in a population of 374 patients with severe congenital neutro penia, regardless of their genetic diagnosis 16, 17 . Of note, in this study, the risk of leukaemia increased with the dose of GCSF, as lessresponsive patients, who required higher doses of GCSF, had a cumulative incidence of leukaemia of 40% after 15 years compared with 11% in more responsive patients 16, 17 . The proposed inter pretation was that a poor response to GCSF defines an 'atrisk' population of patients with severe congenital neutropenia and predicts an adverse outcome. In the French Neutropenia Registry at the time of the analysis, 13 cases of leukaemia were recorded among 231 patients who were observed for a total of 3,166 personyears 19 . The cumulative incidence of MDS or AML was 2.7% at 10 years and 8.1% at 20 years 19 . In the SCNIR, 44 cases of leukaemia were recorded among 374 patients who were observed for a total of 2,043 personyears 16, 17 . The main difference in the methodologies of these two stud ies was the inclusion of patients who did not receive GCSF in the French Neutropenia Registry, whereas all patients in the SCNIR analysis had received GCSF. Of note, in patients with SBDS mutations (which cause Shwachman-Diamond syndrome (TABLE 1)), the risk was comparable to that of patients with ELANE or HAX1 mutations 17 .
Mechanisms/pathophysiology
The establishment of the SCNIR and several national registries has enabled genetic and molecular studies to be performed in these rare disorders and prompted the identification of mutations in >20 genes that impair the neutrophil differentiation programme (FIG. 3) .
Germline mutations ELANE mutations. The majority of patients with auto somal dominant severe congenital neutropenia harbour heterozygous ELANE mutations 20, 21 . ELANE encodes
Box 1 | Cyclic neutropenia
Cyclic neutropenia (a type of severe congenital neutropenia) is an autosomal dominant disorder that is characterized by oscillating numbers of blood neutrophils, monocytes, platelets, reticulocytes and lymphocytes (see the figure) , usually with a 21-day periodicity 12, [134] [135] [136] [137] [138] . Mutations in ELANE can cause cyclic neutropenia and other types of severe congenital neutropenia 21, 23 , and, although there is some overlap, genotypephenotype correlations indicate that there is a cluster of mutations that are more likely to be associated with cyclic neutropenia [22] [23] [24] . Cyclic neutropenia has a lower risk of evolution to myelodysplastic syndrome and acute myeloid leukaemia and milder morbidity 23 . However, when neutrophil counts are at the lowest point, patients regularly have painful mouth ulcers, respiratory symptoms, cellulitis, abscesses and severe infections that could be fatal 12 .
The central pathophysiological mechanism of cyclic neutropenia is failure of the bone marrow to maintain a consistent production of mature neutrophils 20, 21, 139 . When granulopoiesis stops, early myeloid progenitors accumulate, then leave the bone marrow and can be observed in the blood. Severe neutropenia recurs when the bone marrow supply is exhausted. This process then repeats regularly. Researchers have puzzled over the mechanisms of the cycling of neutrophils; several mathematicians have proposed explanations [139] [140] [141] [142] [143] [144] [145] . The first model, by Michael Mackey, postulates that the production of neutrophils is governed by long-range stimulatory factors in a long feedback loop that has a built-in time delay in the maturation of promyelocytes to fully differentiated neutrophils. Cell loss early in this process (at the promyelocyte stage) would be associated with oscillations in blood neutrophil counts [143] [144] [145] . Furthermore, if such cell loss was very severe, there might be no apparent oscillations, because neutrophil counts would remain continually extremely low. Intriguingly, treatment with granulocyte colony-stimulating factor in patients with cyclic neutropenia does not abrogate cycling, but increases the absolute neutrophil count, shortens the cycle periodicity from the usual 21 days to about 14 days and prevents serious infections neutrophil elastase, which is a cytotoxic serine pro tease that is stored in azurophil granules and is released after neutrophil activation. Neutrophil elastase hydro lyses multiple protein substrates, including cell surface proteins (such as GCSF receptor (GCSFR), vascular cell adhesion protein (VCAM), mast/stem cell growth factor receptor Kit (KIT) and CXCchemokine recep tor 4 (CXCR4)). It is also involved in the function of neutro phil extracellular traps (networks of fibres that bind patho gens) [20] [21] [22] . More than 200 different ELANE mutations have been identified, which are randomly distrib uted over all exons as well as in intron 3 and intron 4 (REFS [22] [23] [24] . There is substantial overlap in the mutations that cause severe congenital neutro penia and in those that cause cyclic neutropenia, revealing that genotyping alone is not sufficient to establish a clinical diagnosis [23] [24] [25] [26] . Some ELANE mutations, such as p.C151Y or p.G214R, cause a moresevere pheno type in terms of increased risk of leukaemo genesis, poor response to GCSF and risk of severe infections 16 . In addition, there are cases of pheno typically healthy parents with mosaicism of ELANE mutations (that is, those who harbour two populations of cells, one with ELANE mutations and the other with wildtype ELANE) whose children have inherited neutropenia in an autosomal dominant manner 27, 28 . HAX1 mutations. Homozygous mutations in HAX1 can be found in patients with autosomal recessive congenital neutropenia, especially in consanguineous pedigrees, such as families in whom severe congenital neutro penia was originally described 4, 29, 30 . There are two HAX1 splice isoforms, and genotype-phenotype studies have shown that HAX1 mutations affecting both isoforms (mainly p.Q190X in the original patients and p.R86X in Japanese patients) cause severe congeni tal neutropenia with neurological symptoms 31, 32 (for example, develop mental delay and epileptic seizures). Mutations that affect only one isoform (mainly p.W44X, which is found in consanguine ous families of Turkic origin) lead to severe congenital neutropenia without neurological involvement 30 . HAX1 is a ubiquitously expressed protein, but the binding partner of HAX1, haematopoietic lineage cell specific protein (HCLS1), is an essential adaptor protein of GCSFR signalling 33, 34 . Indeed, mice with deletions of Hcls1 are neutropenic 33 . In patients with HAX1 mutations, neutropenia prob ably results from the abrogated activation of HCLS1 and its downstream signalling, which is essential for granulopoiesis.
Mutations causing extra-haematopoietic abnormalities.
Severe congenital neutropenia could also be caused by rare mutations (FIG. 3) that lead to severe neutropenia in combination with nonhaematopoietic organ failures ( 
39
) and the liver (glycogen storage; SLC37A4 (REFS 40, 41) ) (TABLES 1,2). These mutations affect vari ous functions of haematopoietic stem cells and myeloid cells 21, 30 (FIG. 4) .
Multigenic mutations. Intriguingly, some patients with severe congenital neutropenia harbour inherited muta tions in more than one neutropeniaassociated gene. Combinations of G6PC3 and ELANE or HAX1 and ELANE mutations have been reported 42 . In the HAX1 and ELANE combination, the influence of each mutation . In 1956, Rolf Kostmann described for the first time the autosomal recessive inheritance of familial agranulocytosis and named it 'infantile genetic agranulocytosis' (REF. 29 ). Subsequently, the term 'Kostmann syndrome' was used for many years for patients with severe congenital neutropenia. In 1959, a family with dominant inheritance of neutropenia was reported for the first time 149 , and in 1970, severe congenital neutropenia was first recognized as a pre-leukaemic syndrome 9 . Recombinant human granulocyte colony-stimulating factor (G-CSF; for example, filgrastim and lenograstim) was cloned and produced in 
CXCR2

Congenital neutropenia
Myelokathexis due to impaired neutrophil release from the bone marrow to the peripheral blood
None
EIF2AK3
Wolcott-Rallison syndrome None
Early infancy-onset insulin-dependent diabetes mellitus, epiphyseal dysplasia, growth retardation, hepatic and renal dysfunction, developmental delay and exocrine pancreatic deficiency is hard to analyse, as both mutations lead to severe neutro penia. In combinations of G6PC3 with ELANE or HAX1, patients may show symptoms of both inherited mutations 42 . The additional mutation besides the driving monoallelic autosomal or biallelic recessive mutations may have an influence on the disease severity. Next generation sequencingbased evaluation of all known neutropeniacausing mutations will probably reveal more cases of digenic or even multigenic mutations and will lead to a better understanding of the influence of each mutation.
Germline CSF3R mutations. Of note, germline biallelic CSF3R mutations that affect the extracellular part of GCSFR and lead to reduced or completely abro gated GCSF signal transduction have been reported in rare cases of severe congenital neutropenia [43] [44] [45] . The pattern of inheritance (whether dominant or recessive) of these mutations can vary (TABLE 1) . Interestingly, some patients with germline biallelic CSF3R mutations respond to GMCSF 43 .
Pathological mechanisms
The dysregulated molecular pathways that underlie the arrest of granulopoiesis at the promyelocyte stage can vary based on the different genetic aetiologies. However, some pathological mechanisms are shared by different mutations. We focus our discussion on the mechanisms that are better characterized, owing to the larger numbers of patients with a common aetiology.
Endoplasmic reticulum stress and apoptosis of myeloid cells. Mutant neutrophil elastase could not be properly folded, processed, secreted or degraded in myeloid cells of patients with severe congenital neutropenia associated with ELANE mutations, depending on which elastase Poor or no response to granulocyte colony-stimulating factor (G-CSF) in some patients. § Dominant, homozygous recessive or compound heterozygous recessive.
||
No response to G-CSF, good response to granulocyte-macrophage colony-stimulating factor (GM-CSF) with increased granulocyte counts.
domain was affected by the mutation 46, 47 . In addition, a neutropeniaassociated ELANE mutation that dis rupts the start of translation generates a shorter form of neutrophil elastase, which leads to aberrant localiza tion of the mutated protein 48 . Intracellular accumu lation and mislocalization of mutant neutrophil elastase induce endoplasmic reticulum (ER) stress and activate the unfolded protein response (UPR) [49] [50] [51] [52] , leading to increased apoptosis associated with the upregulation of the master ER chaperone 78 kDa glucoseregulated pro tein (GRP78), XBP1 mRNA splicing and activation of ATF6 (REFS [49] [50] [51] [52] . The magnitude of UPR activation varies with different ELANE mutations [49] [50] [51] [52] . Interestingly, drastically diminished levels of ELANE mRNA in pro myelocytes and neutrophil elastase in the plasma of patients with severe congenital neutropenia have been reported 53, 54 , a finding that questions how these low levels of mutated protein could induce the UPR. It is also not clear why the same ELANE mutations activate the UPR in patients with severe congenital neutropenia but not in patients with cyclic neutropenia. Patients with severe congenital neutropenia have diminished levels of antileukoproteinase (SLPI), the natural inhibitor of neutrophil elastase, in promyelocytes and plasma 55 . SLPI might regulate the extent that the UPR is triggered by mutant neutrophil elastase, and, therefore, a deficiency in SLPI might explain how even low levels of mutant neutro phil elastase can induce the UPR. Patients with cyclic neutropenia have normal levels of SLPI, which could protect cells from the UPR. Expression of the ER stress related proteins GRP78 and phosphorylated eukaryotic translation initiation factor 2A (eIF2A) is also increased in neutrophils from patients with G6PC3 mutations 35 . Increased apoptosis was observed in the bone marrow myeloid progenitor cells of patients with severe congen ital neutropenia with ELANE or HAX1 mutations 47, 56, 57 . Diminished expression of the anti apoptotic proteins (apoptosis regulator Bcl2 (BCL2), BCL2associated agonist of cell death (BCLX L ) and baculoviral IAP repeatcontaining protein 5 (also known as apopto sis inhibitor survivin)), but increased expression of BCL2related protein A1 (also known as BFL1) and the antiapoptotic isoform of induced myeloid leukae mia cell differentiation protein MCL1, was detected 56, 57 . HAX1 is also expressed in mitochondria, where it func tions as an antiapoptotic protein; mutated HAX1 causes apoptosis of myeloid progenitors by loss of mitochon drial function 30 . Furthermore, mitochondrial release of cytochrome c was increased in myeloid progenitors from patients with HAX1 mutations but not in controls 30, 47 . Interestingly, these patients had increased levels of sur vivin in myeloid cells 58 . Morphological studies and lab oratory evidence suggest that apoptosis and the removal of the weakened cells by bone marrow macro phages are the final step in this pathway. Neutrophils from patients with JAGN1 (which encodes protein jagunal homologue 1) mutations also revealed increased apop tosis 59 . An aberrant glycosylation of neutrophil proteins (for example, NADPH oxidase) was reported in patients with G6PC3 and SLC37A4 mutations, which led to increased ER stress and apoptosis 35, 60 .
Deregulated expression of transcription factors.
In addition to neutropenia, the majority of patients with severe congenital neutropenia have increased counts of monocytes and eosinophils (twofold to four fold above normal) 61 . Monocytosis could be explained as a compensatory mechanism of innate immuno logical defence in the absence of neutrophils. It might also be a consequence of the deregulated signalling of the tran scription factors that are responsible for the commit ment of the myeloid progenitors towards neutrophils or monocytes 62, 63 . In patients with severe congenital neutropenia, the expression of the granulopoiesis activating protein CCAAT/enhancerbinding proteinα (C/EBPα) is severely diminished and the expression of the monopoiesisactivating transcription factor PU.1 (PU.1) is unaffected or slightly increased 64, 65 . Thus, dis turbed C/EBPα:PU.1 expression ratio with a strong shift towards PU.1 expression might have a decisive role in the dysregulation of myelopoiesis in severe congenital neutro penia. Increased blood and bone marrow eosino phil counts are also a common finding in patients with severe congenital neutropenia 61 . Constitutive expression of the transcription factor DNAbinding protein inhib itor ID1 (ID1) in human haematopoietic cells modestly enhanced neutrophilic differentiation and inhibited eosinophilic development 66 . GCSF upregulates ID1 in myeloid progenitor cells of healthy individuals, but not in patients with severe congenital neutropenia. Thus, defective ID1 expression may cause eosinophilia and may contribute to the lack of neutrophilic granulocytes in patients with severe congenital neutropenia 65 . 
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Other rare causes of neutropenia* 6% Osteopetrosis; granulopoiesis has not been studied yet
G-CSFR signal transduction
The GCSF signalling pathway is altered in patients with severe congenital neutropenia because of the mutations in the genes involved in GCSF signalling. This explains why therapy with a very high therapeutic dose of GCSF is effective in most cases. Patients with severe congenital neutropenia have no defects in GCSF production or in GCSFR expression (their serum contains increased levels of GCSF 67 and myeloid cells express increased levels of GCSFR 68 ). Dysregulation in the GCSFR signal trans duction occurs at the level of effector proteins down stream in the pathway, leading to severe deregulation of transcription of genes that promote myeloid cell prolifer ation or differentiation 65, [69] [70] [71] [72] [73] (FIG. 5) . The consequence of this altered protein expression profile is diminished or absent neutrophil differentiation.
Mechanisms of G-CSF therapy.
By increasing the stimu lation of GCSFR signalling, GCSF therapy induces com pensatory mechanisms of granulopoiesis in patients with severe congenital neutropenia. The enzyme nicotinamide phosphoribosyltransferase (NAMPT) is necessary for the activation of the NAD + dependent protein deacetylase sirtuin 1 (SIRT1), which in turn activates the transcrip tion factors C/EBPα and C/EBPβ in healthy individuals. C/EBPα is responsible for steadystate granulopoiesis, whereas C/EBPβ is crucial for 'emergency' granulo poiesis 74 , which is normally required in situations such as infections. In patients with severe congenital neutro penia, GCSF treatment activates the NAMPTinduced and SIRT1induced C/EBPβdependent granulopoiesis 75 (FIG. 5) . The levels of NAMPT and SIRT1 were markedly increased in myeloid cells and in plasma from GCSF treated patients compared with healthy individuals 75 . Interestingly, nicotinamide (also known as vitamin B 3 ), the substrate of NAMPT, is capable of increasing the ANC in healthy individuals 75 and is considered for clinical use in patients with severe congenital and cyclic neutropenia.
Leukaemic progression
Severe congenital neutropenia should be regarded as a preleukaemic condition, whereby a substantial propor tion of patients develop leukaemia 9, 16, 17, 19, [76] [77] [78] [79] [80] , predomin antly AML (undifferentiated (M0), myeloblastic (M1) or myelomonocytic (M4)), but acute lymphoblastic leu kaemia 81 and chronic myelomonocytic leukaemia 82 have also been reported. Leukaemic progression is not restric ted to patients with ELANEassociated severe congeni tal neutro penia. In the European branch of the SCNIR, 17 out of 118 patients with ELANE mutations (14.4%) and 6 out of 48 patients harbouring HAX1 mutations (12.5%) have developed leukaemia 83 . Of the 88 patients with Shwachman-Diamond syndrome, 7 developed leukae mia (9%). However, the number of patients in most other genetic subgroups of congenital neutropenias is too small to make any reliable statement about the risk of develop ing leukaemia. Studies on individual patients, regard less of their genotype, including a patient with cyclic neutropenia 84 , have reported leukaemic progression.
CSF3R mutations. A major risk factor for leukaemo genesis in patients with severe congenital neutropenia is the presence of somatic (acquired) CSF3R mutations (mostly C to T nonsense mutations that convert gluta mine codons into premature stop codons) that result in the truncation of approximately 100 amino acids of the cytoplasmic domain of GCSFR (FIG. 6) . Functional studies in murine myeloid cell lines showed that these truncated GCSFRs blocked GCSFinduced neutro phil differentiation and maturation in these cell line models 85, 86 . This observation fuelled the concept that the membranedistal carboxyterminal region of GCSFRs harboured a 'differentiation domain' from which specific differentiation signals emanated [85] [86] [87] . Extended mutation analysis has shed further light on the crucial functions of the GCSFR C terminus, which have been reviewed in detail elsewhere 88, 89 . GCSFR truncation mutants show prolonged halflife at the plasma membrane and, therefore, act dominantly over the wildtype receptors 90 , resulting in an increased GCSFinduced proliferative response and sustained activation of signal transducer and activator of transcription 5 (STAT5) in myeloid pro genitors 91, 92 , which could promote the clonal expansion of haematopoietic stem cells and progenitor cells 93 .
The presence of acquired CSF3R nonsense truncating mutations has been shown in the leukaemic haemato poietic clones of patients with severe congenital neutro penia who progress to MDS or AML 90, [94] [95] [96] . The frequency of CSF3R mutations in patients with severe congenital neutropenia was estimated at around 30-35% in patients without leukaemia, compared with approximately 80% in those who also had AML or MDS, supporting the association between the acquisition of CSF3R mutations and leukaemic transformation 78 . Importantly, multiple haematopoietic clones with distinct CSF3R mutations frequently coexist in the same patient, indicating a strong selective pressure that favours the expansion of such clones 78 . The time between the first detection of clones with CSF3R mutations and signs of malignant transfor mation is highly variable: some patients progressed to MDS or AML within a few months 78, 96 , whereas others did not develop leukaemia for many years, even if they had high numbers of mutated haematopoietic clones, indicating that additional cooperating events are involved in malignant transformation 78, [97] [98] [99] [100] . A crucial question that emerged from the discovery of myeloid haematopoietic clones harbouring somatic CSF3R mutations was whether, and if so how, GCSF treatment has an effect on the proliferation of such clones. Data from longterm followup studies of patients with severe congenital neutropenia (in whom CSF3Rmutant clones were detected) who received GCSF indicated that the percentage of CSF3Rmutant clones did not systematically increase and, sometimes, even tempor arily declined during GCSF treatment 78, 98 . However, this decline does not necessarily mean that these clones have disappeared entirely, as it might simply be a matter of the sensitivity of the detection method. Recently, nextgeneration deep sequencing has been established as a highly sensitive analy sis technology that enables the detection of haematopoietic stem cell clones harbouring CSF3R mutations that occur with a frequency of <1% 98, 99 . We have hypothesized that, if one of these clones is hit by a second leukaemia associated mutation, it will acquire a proliferative advantage that would ultimately lead to overt leukaemia 98, 99 .
Acquisition of a second leukaemia-associated mutation.
In a collaborative study involving patients from differ ent registries, the patterns of acquisition of leukaemia associated mutations in haematopoietic stem cell clones were investigated using nextgeneration sequencing 98, 99 . Of the 31 patients who had progressed to MDS or AML, 20 (64.5%) had clones with mutations in RUNX1 and these mutations mostly occurred in clones that had already acquired CSF3R mutations. This pattern was seen in patients with severe congenital neutropenia associated with mutations in ELANE, HAX1, SLC37A4 (also known as G6PT1), GFI1 and WAS
.
The time course between acquisition of one or more leukaemiaassociated mutations and the development of leukaemia varies considerably 97, 98 . Thus, CSF3R and RUNX1 mutational analyses cannot be used for diagnostic purposes, but can be helpful to screen for the risk of malig nant transformation. The presence of these mutations is Nature Reviews | Disease Primers
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a strong predictor of later leukaemic development and, therefore, should result in a moreintensive diagnostic monitoring to evaluate the growth of pre leukaemic cell clones. Screening for CSF3R, RUNX1 and other (less fre quent) mutations associated with secondary malignancies, such as mutations in ASXL1, SUZ12, EP300, NPM1 and FIZ1 internal tandem duplication, is advised 97, 98 . The high frequency of cooperating RUNX1 and CSF3R mutations in patients with severe congenital neutropenia suggests a novel and unique molecular pathway of leukaemo genesis, which is not seen thus far in any other type of adult or paediatric malignancy 98 (FIG. 7) . Independent from the genetic subtypes, leukaemic progression in patients with severe congenital neutropenia is often preceded by one or more chromosomal abnormalities, such as monosomy 7 and trisomy 21 (REF. 98 ).
Diagnosis, screening and prevention Diagnosis Presenting signs and symptoms. Severe congenital neutro penia is usually diagnosed during early childhood. In neonates, a diagnostic clue could be an acute and severe umbilical infection, which can occur within the first days of life. During the first weeks of life, the child might begin to have fevers associated with respir atory symptoms, including signs of pneumonia 13 . During the first month of life, skin infections or deep tissue abscesses might present. Severe gingivitis and periodontitis (FIG. 8) can develop within the first 2 years of life 101 . There are often long delays between the first symp toms and the confirmation of the diagnosis. Children who present with fever and symptoms of a respiratory or skin infection do not routinely receive a white blood cell count with differential count to discover neutropenia; in most cases, these common problems are not caused by severe congenital neutropenia. Furthermore, neutro penia in early childhood is commonly an auto immune dis order 102, 103 , which usually remits spontane ously over the first 3 or 4 years of life, so low ANCs are often dismissed as unconcerning. Early diagnosis of severe congenital neutropenia depends on a skillful clin ician recognizing that recurrent fevers and infections suggest an under lying haematological or immunological problem. The most relevant clue often is that the patient is moreseverely ill than would be expected. Recurrent and painful mouth sores or teeth or gums problems are other important clues to prompt blood cell counts (FIG. 8) .
When neutropenia is one of the manifestations of a syndrome (TABLES 1,2) , the other features, such as organ failures, diarrhoea, malabsorption and failure to thrive, among other features, are often recognized first and the diagnosis of severe congenital neutropenia follows. It cannot be overemphasized that a careful physical examination is the crucial starting point for the diag nosis of severe congenital neutropenia. In addition, the family history is extremely important to determine whether there are multiple individuals in the same family with the same or similar medical problems and if the patient's parents are consanguineous.
Blood neutrophil counts.
Patients with severe congeni tal neutropenia have chronically reduced ANCs, but the blood counts are first measured when the patient has a fever and infections, and, therefore, in this occasion, the ANC might be a little higher or even lower than it usually would be for this specific patient. The stress of inflammation might mobilize all of the available neutro phils from the bone marrow reserves, thereby raising the ANC, but the stress of infection could also exhaust the supply, thereby leading to a moreextreme degree of neutropenia. For instance, ANCs of >0.5 × 10 9 cells per l without GCSF treatment are quite rarely seen in patients with severe congenital neutropenia due to mutations in ELANE, HAXI or G6PC3 (REFS 13, 14, 35) , not even during infection, whereas patients with autoimmune neutro penia can have ANCs of >1 × 10 9 cells per l during bacterial infections 102 . Tyrosine-protein phosphatase non-receptor type 11 (PTPN11; also known as SHP2) is another component of G-CSF signal transduction; SHP2 induces dephosphorylation and, thereby, activation of the tyrosine-protein kinase Lyn, which in turn, in association with the tyrosine kinase Syk, phosphorylates and activates haematopoietic lineage cell-specific protein (HCLS1), inducing myeloid differentiation of haematopoietic cells 33, 34, 71, 72 . Substantially increased levels of SHP2 have been observed in neutrophils from patients with severe congenital neutropenia 73 . In addition, lymphoid enhancer-binding factor 1 (LEF1), a transcription factor member of the WNT signalling pathway, is severely diminished in myeloid progenitors of patients with severe congenital neutropenia 64 . LEF1 activates the granulocyte-specific transcription factor CCAAT/enhancer-binding protein-α (C/EBPα), CCND1 and MYC, as well as the anti-apoptotic factor baculoviral IAP repeat-containing protein 5 (also known as survivin) 64 . Expression of all these proteins is severely diminished in myeloid cells of patients with severe congenital neutropenia, along with reduced activity of phosphoinositide 3-kinase (PI3K), AKT, HCLS1-associated protein X1 (HAX1) and HCLS1 (REFS 33, 34) . As a consequence, G-CSF therapy activates nicotinamide phosphoribosyltransferase (NAMPT) and through this the compensatory emergency granulopoiesis pathway; NAMPT converts nicotinamide into nicotinamide adenine dinucleotide (NAD time 104 . For these reasons, it is very helpful to obtain a series of blood counts once or twice a week for 2-3 weeks and during an infectionfree episode in patients who are suspected of having severe congenital neutropenia.
Bone marrow examination. If severe congenital neutro penia is suspected, bone marrow examination is useful as an early step in diagnosis. At the initial examin ation, biopsies as well as aspirates are helpful to rule out (or confirm) leukaemia, aplastic anaemia or myelo dys plasia. Typical findings in the bone marrow of patients with severe congenital neutropenia are increased numbers of promyelocytes and myelocytes and a paucity of metamyelocytes, band cells and mature neutrophils 105 , indicating maturation arrest of granulo poiesis. Quantitatively, the bone marrow can be described with the myeloid:erythroid cell ratio and the immature:mature myeloid cell ratio. To obtain results that are representative of the baseline conditions, it is important to do the bone marrow examination when the patient is in a reasonably stable condition (that is, after treatment is given for an acute infection). In most patients, the morphology of the myeloid cells is not indicative of the cause of neutropenia 105 . Cytogenetic tests to exclude chromosomal aberrations are done on the initial bone marrow sample, although the result is almost always normal at the time of diagnosis. It is very useful to save some unstained slides and a frozen sample of bone marrow cells from patients for future research, whenever possible. For instance, if a patient develops leukaemia, it is helpful to examine earlier samples to detect leukaemiaassociated mutations, to improve our understanding of the pattern of leukaemogenesis.
Genetic analyses. The pattern of inheritance can assist in confirming the diagnosis. For example, auto somal domin ant mutations in ELANE [20] [21] [22] are the most common cause of cyclic neutropenia and severe congen ital neutropenia (BOX 1; TABLE 1). Mutations in ELANE should be suspected and might be recognized in the first months of life if a child is ill and a family member already has the diagnosis of severe congenital neutro penia associated with ELANE mutations. Conversely, patients affected by diseases that are inherited in a reces sive manner, for example, severe congenital neutro penia due to mutations in
, among others, are usually the first member of their family to receive the diagnosis of severe congenital neutropenia. Severe congenital neutro penias associated with mutations in TAZ 36 (which cause Barth syndrome) or WAS 106 have Xlinked inheritance. Genetic testing is having an increasingly central role in diagnosing severe congenital neutropenia. Germline mutations can be identified by DNA sequencing of blood, saliva or another tissue sample. Clinical clues that point to a syndrome matching the patient's presentation can help to determine which gene should be tested first (TABLE 1) . For instance, in an infant with neutro penia who also presents with gastrointestinal symptoms, short stature and failure to thrive (which are common manifestations of Shwachman-Diamond syndrome), SBDS should be sequenced. Similarly, a young boy with neutropenia, shortness of breath and symptoms of heart failure (which are indications of Barth syndrome) should have TAZ sequenced first, or a patient with severe neutropenia, urogenital or heart deformities should be sequenced for G6PC3.
When there are no congenital organ anomalies or other clinical clues, the standard approach for chil dren who present with severe neutropenia and whose bone marrow examination shows maturation arrest is sequencing candidate genes that have been associated with severe congenital neutropenia. It is reasonable to sequence ELANE first, as it is the most common muta tion. As ELANE mutations can cause severe congenital neutropenia or cyclic neutropenia [22] [23] [24] , sequential blood counts at regular intervals, possibly every day or every other day, are needed to make the diagnosis of cyclic neutropenia with greatest confidence. If a heterozygous mutation in ELANE is found, most clinicians do no further genetic testing. If ELANE sequencing is negative, Nature Reviews | Disease Primers The native mature granulocyte colony-stimulating factor receptor (G-CSFR; encoded by CSF3R) consists of 836 amino acids, whereas the truncated forms of G-CSFR usually vary between 715 and 790 amino acids in length. Truncated G-CSFRs lack the ability to undergo endocytosis, owing to the deletion of a di-leucine motif that is essential for internalization 154 . Furthermore, they are hampered in endosomal trafficking and lysosomal degradation, owing to the loss of phospho-tyrosine Y729 (which is the binding site of suppressor of cytokine signalling 3 (SOCS3)), which mediates ubiquitylation of a crucial membrane-proximal lysine residue
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. G-CSFR forms dimers upon activation by granulocyte colony-stimulating factor (G-CSF). Both wild-type G-CSFR homodimers and wild-type truncation mutant G-CSFR heterodimers are subject to normal internalization and lysosomal degradation, whereas the homodimeric truncation mutants accumulate at the plasma membrane. Owing to their prolonged half-life and residence time at the plasma membrane, the G-CSFR truncation mutants act dominantly over the wild-type G-CSFR 90 , resulting in an increased G-CSF-induced proliferative response and sustained activation of signal transducer and activator of transcription 5A (STAT5A) and phosphoinositide 3-kinase (PI3K)-AKT signalling in myeloid progenitors 91, 92 . Sustained activation of STAT5A seems to be essential for the clonal expansion of haematopoietic stem cells and progenitor cells in mice that harbour the Csf3r d715 truncation mutation 93 , whereas prolonged activation of PI3K-AKT signalling resulted in the increased production of intracellular reactive oxygen species (ROS), particularly hydrogen peroxide (H 2 O 2 ), in mice myeloid progenitors via activation of NADPH oxidase complex 2 (NOX2) 92 . Increased levels of H 2 O 2 inactivate oxidation-sensitive phosphatases (such as tyrosine-protein phosphatase non-receptor type 1 (PTPN1) and phosphatase and tensin homologue (PTEN)) that might negatively control G-CSF signalling and cause oxidative damage to proteins, lipids and nucleotides. JAK2, Janus kinase 2; MAPK, mitogen-activated protein kinase.
other individual genes could be analysed, on the basis of family history and available resources. In consanguine ous families, the search for autosomal recessive muta tions would be recommended (starting with HAX1). If these tests are also negative, sequencing of a panel of neutropeniaassociated genes or wholeexome sequenc ing would be recommended. The panel sequencing approach is being used increasingly as a first choice and could be ultimately less expensive and more informative, as it can also uncover multigene mutations 105 . Genetic testing is becoming increasingly precise, but the mechanisms whereby the mutated protein causes the patient's specific disease features are still poorly understood. Different neutropeniaassociated ELANE mutations have consequences of different severity 16, 17 . Longitudinal records of the SCNIR show that no cases of MDS or AML have occurred in patients with some speci fic ELANE mutations in many patientyears of observation 23 , and careful statistical analysis shows highly significant genotype-phenotype correlations for these mutations 23 . It should not be surprising that mutations associated with morebenign phenotypes are prevalent. Longitudinal followup of patients to deter mine the clinical significance and prognostic importance of specific neutropeniaassociated mutations is a vital function of patient registries.
A common problem with genetic diagnosis is the find ing of novel variants of unknown clinical signifi cance. An initial step to determine the significance of the genetic variant is to map it through an extensive family study, to rule out family segregation. Wholeexome sequencing would be a reasonable next step, if available, using global databases as control to identify common non pathogenic variants; this approach can lead to the discovery of new causes of neutropenia 107 . It is usually best to review genetic findings in light of a registry and repository that are focused on the neutropeniacausing genes. In the European branch of the SCNIR, in 22% (118 out of 537 patients) of the registered patients, a genetic diagnosis could not be obtained so far.
Immunological diagnostics. Young children with neutropenia are commonly tested for antineutrophil autoantibodies 102 . These tests are useful to support a suspected diagnosis of autoimmune neutropenia, but they are not definitive. In a substantial proportion, prob ably at least onethird, of children with presumed auto immune neutropenia, test results are negative even with repeated testing. Conversely, antineutrophil autoanti bodies have also been reported in patients with severe congenital neutropenia 108, 109 . When evaluating patients who present with fever, infections and neutropenia, it is good practice to initially take a broad approach to assess the immunological status: lymphocyte counts, lymphocyte subset numbers and immunoglobulin levels should be measured. Most patients with severe congenital neutropenia have normal or even increased lymphocyte counts 61 , increased blood monocyte counts 61 and normal or increased immuno globulin levels, whereas patients with immuno deficiency syndromes usually also have lymphocytopenia and immunoglobulin deficiencies, and they might have severe neutropenia. Warts, hypogammaglobulin aemia, infections and myelokathexis (WHIM) syndrome is a unique condition that should be considered in patients with warts, severe lymphocytopenia and severe neutro penia, who often have a total white cell count of <1 × 10 9 cells per l.
Screening
It is not routine practice to perform blood cell counts in infants at birth or in the first week of life. The inci dence of severe congenital neutropenias is considered too low to justify this practice. Blood counts are also not routinely done when children present with febrile illnesses, again, because these illnesses are common in the general population.
Prevention
Prevention of these genetic disorders is challenging. Genetic counselling that clearly presents all of the options for diagnosis and management is the mainstay for excel lent care, and the body of evidence on which counselling is based is rapidly evolving. Prenatal genetic diagnosis (through amniocentesis) is possible for the autosomal dominant disorders, whereas, for the recessive dis orders, DNA sequencing of potential parents in addition to genetic counselling might help parents to understand the risk of having affected offspring. Genetic testing should also be offered to relatives of patients with recessive dis orders, especially if they are eligible as a haematopoietic stem cell donor for the affected family member.
Another important aspect is prevention of the con sequences of neutropenia. In addition to early GCSF treatment, maintaining excellent oral hygiene, good nutritional status and healthy living patterns can help to reduce the risk of infections, whereas there is no substan tial evidence supporting the benefit of prophylactic anti biotics. The use of myeloid growth factors is a preventive strategy (see below). As discussed, the risk of leukaemic transformation can be managed with regular screening for somatic mutations or karyotype anomalies.
Management
Initiation of G-CSF therapy at diagnosis
GCSF is the firstchoice treatment in almost all patients with severe congenital neutropenia or cyclic neutro penia (FIG. 9) who require GCSF treatment to achieve and maintain blood ANCs of >1 × 10 9 cells per l . In general, at the beginning of treatment, GCSF is given daily subcutaneously; by starting with a low dose (1-3 μg per kg per day) or moderate dose (5 μg per kg per day) in patients with cyclic neutropenia or severe congenital neutropenia, respectively, the adverse effects (including bone pain, headache and myalgias) can be generally avoided. The dose is gradually increased in some patients at about 10-14 day intervals until the patient consistently maintains an ANC of >1 × 10 9 cells per l (REF. 101 ), which is a threshold that is usually sufficient to ameliorate the symptoms. The genetic subtype does not correlate well with the GCSF dose needed to raise the ANC to this level 110 . GCSFtreated patients should have their blood counts measured at least several times per year to assure proper treatment. The patient is considered a 'non responder' at GCSF dosages of >50 μg per kg per day and ANCs of <0.5 × 10 9 cells per l, but some experts use a lower threshold (25 μg per kg per day) for defining a nonresponder or a poor responder 83, 111 . These patients should be at least considered as candidates for haemato poietic stem cell transplantation (HSCT), based on data from the SCNIR 83 . GCSF is most effective as a preventive treatment, but patients with severe congenital neutro penia who present with infections should start receiving a combination of GCSF and antibiotics as soon as possible.
Long-term management
Owing to the various genetic subtypes of severe congeni tal neutropenia, most with additional clinical features (TABLES 1,2), the longterm management of patients usually requires the cooperation of a team of specialists who see the patient on a regular basis. GCSF therapy can correct the neutropenia in, for example, ShwachmanDiamond syndrome, Barth syndrome and others, but it does not alter most of the other manifestations of these conditions.
Most patients on GCSF treatment can maintain a normal or nearnormal ANC, but they may still experi ence some infections and develop gingivitis and perio dontitis. Failure to comply with the need for continuous treatment is the most common reason for treatment failures. Consistent dental care is particularly impor tant because once the integrity of the dental-gingival barrier to prevent bacterial penetration below the border of the enamel is destroyed, it usually does not recover. Periodontal disease then develops and can last for a lifetime. GCSF treatment can reverse the quantitative deficiency of neutrophils, but the full functions of these cells in patients with severe congenital neutropenia may not be completely restored. Neutrophils from patients have shown defective generation of oxygen radicals and reduced in vitro chemotaxis 112 . CYBB, which encodes a key component of NADPH oxidase, is downregulated in patients with severe congenital neutro penia 113 . Neutrophil dysfunction could also be due to specific defects in the neutrophil bactericidal proteins (for example, deficiency in antibacterial peptide LL37 (also known as catheli cidin antimicrobial peptide)) [114] [115] [116] [117] . However, GCSF treatment has many effects to enhance the functions of neutrophils. It primes the metabolic burst associated with phago cytosis and stimulates the production of several neutrophil antibacterial proteins, and thereby mediates a net increase in the functional activity of neutrophils 118 . The risk of longterm haematological complications, such as the risk of developing AML or MDS, varies con siderably across the spectrum of genetic aetiologies of severe congenital neutropenia. The specific risk for each gene or mutation is difficult to determine, because the number of known cases worldwide is too small and the duration of followup is too short to draw strong conclusions. In patients (both children and adults) with subtypes with a known high risk (for example, mutations in ELANE, HAX1 or SBDS), monitoring with annual bone marrow evaluations, including cytogenetic analyses , and the pattern of disease severity depends on age.
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and CSF3R mutational screenings, is recommended 83, 111 . As karyotype aberrations or leukaemiaassociated mutations, such as in RUNX1, occur before leukaemia 98 , their detection might suggest to initiate bone marrow transplantation before overt leukaemia develops.
The development of earlyonset osteopenia and osteo porosis has been reported in approximately 40% of patients with severe congenital neutropenia, based on bone density measurements 119 . The underlying patho logical mechanisms are still unclear, and, fortunately, fractures are very infrequent events. The development of osteopenia and rarely osteoporosis seems to be indepen dent from the underlying genetic defect, but further genotype-phenotype correlation analyses are required.
Stem cell transplantation
Owing to the efficacy of GCSF therapy, HSCT is no longer essential for saving the lives of patients with severe congenital neutropenia. However, there are two conditions in which HSCT is the only currently avail able treatment option: patients who do not respond to GCSF treatment [120] [121] [122] [123] and patients who develop AML or MDS 120 . In patients who do not respond to GCSF treat ment, following successful transplantation, patients nor malize their peripheral blood counts and do not require further GCSF treatment. Deciding when the optimal time point for HSCT is in patients who do not respond to GCSF treatment is very difficult, as HSCT could still be too toxic to be recommended in some patients. In the case of patients who develop MDS or AML, the chances of survival are dramatically reduced without HSCT. Before 2000, all patients who received standard chemotherapy for AML without HSCT died, and those treated with chemotherapy followed by HSCT had very poor outcomes: most succumbed from transplantrelated infectious complications, for example, fungal infections and graftversushost disease 120 . Since 2001, only mild chemotherapy instead of standard chemotherapy is used to lower the leukaemic blast load, followed by condi tioning for HSCT. Thus, prognosis for these patients has improved substantially, primarily owing to the practice of anticipating HSCT when possible (for example, as soon as the patient develops first signs of MDS, without wait ing for progression to AML) 124 , avoiding anti leukaemic chemotherapy before HSCT and modifications in the preparative regimens. Lowdose cytosine arabinosid (araC; also known as cytarabine) and thioguanine can be used to reduce peripheral blast counts and treat organo megaly. Chemotherapy regimens similar to those used to treat AML are only warranted in patients who do not respond to this milder treatment and have peripheral blast counts that cannot be maintained below 5 × 10 9 cells per l or who have a rapidly progressing disease or organ involvements -especially pulmonary involvement. The improved evaluation of the haematopoietic stem cell donor might also play a part.
Regardless of the reason for HSCT, the 5year sur vival is approximately 80% for patients enrolled in the European branch of the SCNIR 124 . However, HSCT related morbidity owing to acute or chronic graft versushost disease, bacterial or viral infections and the increased risk for AML and secondary malignancies after chemotherapy or irradiation are still major risks to be considered. With current transplant regimens, the AML relapse rate is low; in an analysis of 136 patients by the European Bone Marrow Transplant group, the 3year eventfree survival was 71% overall 121 . Of note, the authors of this study 121 state that "in a precancerous disease like congenital neutro penia, full donor chimer ism (that is, all haematopoietic cells are donorderived) is very important to achieve in order to prevent the reemergence of predisposed clones. "
Pregnancy
The number of patients with severe congenital neutro penia who reach adulthood and wish to have children is increasing. On the basis of two observational studies, administration of GCSF throughout pregnancy is safe and well tolerated 125, 126 . No noticeable adverse effects have been reported. No major differences in pregnancy outcome and complications in the newborn baby were seen between treated and untreated women 125 . Thus, continuation of GCSF treatment throughout preg nancy in women with severe congenital neutropenia is recommended.
Quality of life
The availability of GCSF therapy drastically changed the quality of life for patients with severe congenital neutro penia and their families 127 . Both life expectancy and the ability to participate in normal life activities improved substantially, owing to decreased risk and fear of dying from infections. The majority of children with severe congenital neutropenia and stable ANCs have no phys ical limitations that prevent them from participating in all aspects of daily life, such as attending kindergarten or school, practicing sports, meeting with friends, and 83, 111 . Regardless of their genetic subtype, the major ity of patients with severe congenital neutropenia now reach adulthood 83, 111 . Many patients desire family plan ning and are prepared to accept the substantial risk of transmitting the neutropenia causing mutation to their offspring. Most adults on GCSF therapy are in good conditions, but data on longterm GCSF treatment are based on a followup period of only about 25 years. The risk of developing a haematological malignancy at any time can negatively influence quality of life. However, with improving longterm survival and decreasing transplantrelated morbidity, outcomes for stem cell transplantation are steadily improving 120, 121, 124 .
Outlook
Since the late 1980s 11 , substantial progress has been made in the diagnosis, understanding of the molecular and genetic heterogeneity, pathophysiology and treatment of patients with severe congenital neutropenia. Early detec tion of severe congenital neutropenia already in the first months of life, GCSF therapy and HSCT have contrib uted to survival rates of >80%. However, regular genetic screening is needed to detect and monitor the molecular events associated with leukaemogenesis 98, 128 . In induced pluripotent stem cells (iPSCs) obtained from patients harbouring ELANE mutations, the neutro phil elastase inhibitor sivelestat promotes the differenti ation of promyelocytes into mature neutrophils 129 (although the mechanism is still unclear). Thus, sivele stat could be an alternative or adjuvant treatment. Furthermore, the use of nicotinamide in addition to GCSF treatment to stimu late emergency granulo poiesis by activating the NAMPT-SIRT pathway 75 might enable the reduction of GCSF dosages, and, therefore, reduce the risk of acquisition of CSF3R mutations and leukaemogenesis.
iPSCs have been generated from somatic cells of patients with either ELANE or HAX1 mutations [129] [130] [131] . With the establishment of efficient protocols for in vitro haematopoietic and myeloid differentiation of iPSCs 132, 133 , these cells could be used as an experimental model to study the pathophysiology of disease. Successful restor ation of defective granulopoiesis in vitro has been achieved by lentivirusbased or CRISPR-Cas9based correction of mutated ELANE or HAX1 in iPSCs [129] [130] [131] . Thus, correction of the underlying gene mutation ex vivo with the CRISPRCas9 technology followed by autologous stem cell transplantation is a promising future therapeutic option.
The discovery of >20 mutated neutropenia causing genes that are responsible for severe congenital neutro penias within the past 20 years was only possible owing to the improvement of sequencing technologies. However, in a substantial number of patients with severe congeni tal neutropenia, no mutations could be detected so far. Careful anamnestic inquiries, genetic counselling and tailored nextgeneration sequencing and bio informatic analysis might help to detect mutations in these patients, especially in those who acquired a CSF3R mutation, as this event is exclusive for severe congenital neutropenias and, therefore, a further confirmation of the diagnosis.
